Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Non Operating Income (2020 - 2022)

Terns Pharmaceuticals (TERN) has disclosed Non Operating Income for 4 consecutive years, with -$9.8 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Non Operating Income fell 1148.47% year-over-year to -$9.8 million, compared with a TTM value of -$7.1 million through Dec 2023, down 1158.91%, and an annual FY2023 reading of -$314000.0, down 361.76% over the prior year.
  • Non Operating Income was -$9.8 million for Q4 2023 at Terns Pharmaceuticals, down from $3.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.5 million in Q3 2023 and bottomed at -$9.8 million in Q4 2023.
  • Average Non Operating Income over 4 years is -$673428.6, with a median of $35500.0 recorded in 2021.
  • Peak annual rise in Non Operating Income hit 24921.43% in 2023, while the deepest fall reached 1148.47% in 2023.
  • Year by year, Non Operating Income stood at -$450000.0 in 2020, then soared by 140.0% to $180000.0 in 2021, then plummeted by 536.67% to -$786000.0 in 2022, then plummeted by 1148.47% to -$9.8 million in 2023.
  • Business Quant data shows Non Operating Income for TERN at -$9.8 million in Q4 2023, $3.5 million in Q3 2023, and -$786000.0 in Q4 2022.